The clinical utility of CA 19-9 in pancreatic Adenocarcinoma: Diagnostic and prognostic updates

Current Molecular Medicine

Volumn 13, Issue 3, 2013, Pages 340-351

  Poruk, K E ^a   Gay, D Z ^a   Brown, K ^a   Mulvihill, J D ^a   Boucher, K M ^a,b   Scaife, C L ^a,b   Firpo, M A ^a,b   Mulvihill, S J ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

Author keywords

Cancer antigen 19 9; Carcinoembryonic antigen; Diagnosis; Pancreatic cancer; Prognosis

Indexed keywords

BILIRUBIN; CA 19-9 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; GEMCITABINE;

ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CANCER REGRESSION; CHEMORADIOTHERAPY; CYSTIC NEOPLASM; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE ASSOCIATION; DISTANT METASTASIS; HUMAN; JAUNDICE; LAPAROSCOPY; META ANALYSIS (TOPIC); NEUROENDOCRINE TUMOR; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS INSUFFICIENCY; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY;

EID: 84877746197     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/1566524011313030003     Document Type: Article

References (95)

1. Koprowski H, Herlyn M, Steplewski Z, Sears HF. Specific antigen in serum of patients with colon carcinoma. Science 1981; 212(4490): 53-5.
2. Koprowski H, Steplewski Z, Mitchell K, Herlyn M, Herlyn D, Fuhrer P. Colorectal carcinoma antigens detected by hybridoma antibodies. Somatic Cell Genet 1979; 5(6): 957-71.
3. Del Villano BC, Brennan S, Brock P, et al. Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9. Clin Chem 1983; 29(3): 549-52.
4. Homma T, Tsuchiya R. The study of the mass screening of persons without symptoms and of the screening of outpatients with gastrointestinal complaints or icterus for pancreatic cancer in Japan, using CA19-9 and elastase-1 or ultrasonography. Int J Pancreatol 1991; 9: 119-24.
5. Kim JE, Lee KT, Lee JK, Paik SW, Rhee JC, Choi KW. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol 2004; 19(2): 182-6.
6. Poruk KE, Firpo MA, Adler DG, Mulvihill SJ. Screening for Pancreatic Cancer: Why, How, and Who? Ann Surg 2013; 257(1): 17-26.
7. Hamanaka Y, Hamanaka S, Suzuki M. Sialyl Lewis(a) ganglioside in pancreatic cancer tissue correlates with the serum CA 19-9 level. Pancreas 1996; 13(2): 160-5.
8. Roback J, Combs MR, Grossman B, Hillyer C. AABB Technical Manual, 16th edition: American Association of Blood Banks; 2008.
9. Takasaki H, Uchida E, Tempero MA, Burnett DA, Metzgar RS, Pour PM. Correlative study on expression of CA 19-9 and DU-PAN-2 in tumor tissue and in serum of pancreatic cancer patients. Cancer Res 1988; 48(6): 1435-8.
10. Tempero MA, Uchida E, Takasaki H, Burnett DA, Steplewski Z, Pour PM. Relationship of carbohydrate antigen 19-9 and Lewis antigens in pancreatic cancer. Cancer Res 1987; 47(20): 5501-3.
11. Uchida E, Tempero MA, Burnett DA, Steplewski Z, Pour PM. Correlative studies on antigenicity of pancreatic cancer and blood group types. Cancer Detect Prev Suppl 1987; 1: 145-8.
12. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24(33): 5313-27.
13. Steinberg W. The clinical utility of the CA 19-9 tumorassociated antigen. Am J Gastroenterol 1990; 85(4): 350-5.
14. Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and therapeutic significance of carbohydrate antigen 19-9 as tumor marker in patients with pancreatic cancer. Oncology 2006; 70(4): 255-64.
15. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7(3): 177-88.
16. Goonetilleke KS, Siriwardena AK. Systematic review of carbohydrate antigen (CA 19-9) as a biochemical marker in the diagnosis of pancreatic cancer. Eur J Surg Oncol 2007; 33(3): 266-70.
17. Ferrone CR, Finkelstein DM, Thayer SP, Muzikansky A, Fernandez-delCastillo C, Warshaw AL. Perioperative CA19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma. J Clin Oncol 2006; 24(18): 2897-902.
18. Kilic M, Gocmen E, Tez M, Ertan T, Keskek M, Koc M. Value of preoperative serum CA 19-9 levels in predicting resectability for pancreatic cancer. Can J Surg 2006; 49(4): 241-4.
19. Maithel SK, Maloney S, Winston C, et al. Preoperative CA 19-9 and the yield of staging laparoscopy in patients with radiographically resectable pancreatic adenocarcinoma. Ann Surg Oncol 2008; 15(12): 3512-20.
20. Kondo N, Murakami Y, Uemura K, et al. Prognostic impact of perioperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2010; 17(9): 2321-9.
21. Barton JG, Bois JP, Sarr MG, et al. Predictive and prognostic value of CA 19-9 in resected pancreatic adenocarcinoma. J Gastrointest Surg 2009; 13(11): 2050-8.
22. Turrini O, Schmidt CM, Moreno J, et al. Very high serum CA 19-9 levels: a contraindication to pancreaticoduodenectomy? J Gastrointest Surg 2009; 13(10): 1791-7.
23. Reni M, Cereda S, Balzano G, et al. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009; 115(12): 2630-9.
24. Berger AC, Garcia M, Jr, Hoffman JP, et al. Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008; 26(36): 5918-22.
25. Humphris JL, Chang DK, Johns AL, et al. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol 2012; 23(7): 1713-22.
26. Hata S, Sakamoto Y, Yamamoto Y, et al. Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer. Ann Surg Oncol 2011; 19(2): 636-41.
27. Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V. Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 2000; 82(5): 1013-6.
28. Willett CG, Daly WJ, Warshaw AL. CA 19-9 is an index of response to neoadjunctive chemoradiation therapy in pancreatic cancer. Am J Surg 1996; 172(4): 350-2.
29. Stemmler J, Stieber P, Szymala AM, et al. Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie 2003;26(5):462-7.
30. Boeck S, Haas M, Laubender RP, et al. Application of a timevarying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer. Clin Cancer Res 2010; 16(3): 986-94.
31. Hernandez JM, Cowgill SM, Al-Saadi S, et al. CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg 2009; 13(2): 349-53.
32. Mery CM, Duarte-Rojo A, Paz-Pineda F, Gomez E, Robles-Diaz G. [Does cholestasis change the clinical usefulness of CA 19-9 in pacreatobiliary cancer?]. Rev Invest Clin 2001; 53(6): 511-7.
33. Safi F, Schlosser W, Kolb G, Beger HG. Diagnostic value of CA 19-9 in patients with pancreatic cancer and nonspecific gastrointestinal symptoms. J Gastrointest Surg 1997; 1(2): 106-12.
34. Frena A. SPan-1 and exocrine pancreatic carcinoma. The clinical role of a new tumor marker. Int J Biol Markers 2001; 16(3): 189-97.
35. Mann DV, Edwards R, Ho S, Lau WY, Glazer G. Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundice. Eur J Surg Oncol 2000; 26(5): 474-9.
36. Morris-Stiff G, Teli M, Jardine N, Puntis MC. CA19-9 antigen levels can distinguish between benign and malignant pancreaticobiliary disease. Hepatobiliary Pancreat Dis Int 2009; 8(6): 620-6.
37. Ong SL, Sachdeva A, Garcea G, et al. Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration. Dig Dis Sci 2008; 53(12): 3213-7.
38. Andriulli A, Gindro T, Piantino P, et al. Prospective evaluation of the diagnostic efficacy of CA 19-9 assay as a marker for gastrointestinal cancers. Digestion 1986; 33(1): 26-33.
39. Aroasio E, Piantino P. Tumor-associated trypsin inhibitor in pancreatic diseases. Scand J Clin Lab Invest Suppl 1991; 207: 71-3.
40. Banfi G, Bravi S, Ardemagni A, Zerbi A. CA 19.9, CA 242 and CEA in the diagnosis and follow-up of pancreatic cancer. Int J Biol Markers 1996; 11(2): 77-81.
41. Benini L, Cavallini G, Zordan D, et al. A clinical evaluation of monoclonal (CA19-9, CA50, CA12-5) and polyclonal (CEA, TPA) antibody-defined antigens for the diagnosis of pancreatic cancer. Pancreas 1988; 3(1): 61-6.
42. Bloomston M, Bekaii-Saab TS, Kosuri K, et al. Preoperative carbohydrate antigen 19-9 is most predictive of malignancy in older jaundiced patients undergoing pancreatic resection. Pancreas 2006; 33(3): 246-9.
43. Cerwenka H, Aigner R, Bacher H, et al. TUM2-PK (pyruvate kinase type tumor M2), CA19-9 and CEA in patients with benign, malignant and metastasizing pancreatic lesions. Anticancer Res 1999; 19(1B): 849-51.
44. Chang MC, Chang YT, Su TC, et al. Adiponectin as a potential differential marker to distinguish pancreatic cancer and chronic pancreatitis. Pancreas 2007; 35(1): 16-21.
45. Cwik G, Wallner G, Skoczylas T, Ciechanski A, Zinkiewicz K. Cancer antigens 19-9 and 125 in the differential diagnosis of pancreatic mass lesions. Arch Surg 2006; 141(10): 968-73; discussion 74.
46. Del Favero G, Fabris C, Plebani M, et al. CA 19-9 and carcinoembryonic antigen in pancreatic cancer diagnosis. Cancer 1986; 57(8): 1576-9.
47. Del Maschio A, Vanzulli A, Sironi S, et al. Pancreatic cancer versus chronic pancreatitis: diagnosis with CA 19-9 assessment, US, CT, and CT-guided fine-needle biopsy. Radiology 1991; 178(1): 95-9.
48. Dianxu F, Shengdao Z, Tianquan H, et al. A prospective study of detection of pancreatic carcinoma by combined plasma K-ras mutations and serum CA19-9 analysis. Pancreas 2002; 25(4): 336-41.
49. Duraker N, Hot S, Polat Y, Hobek A, Gencler N, Urhan N. CEA, CA 19-9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol 2007; 95(2): 142-7.
50. Ehmann M, Felix K, Hartmann D, et al. Identification of potential markers for the detection of pancreatic cancer through comparative serum protein expression profiling. Pancreas 2007; 34(2): 205-14.
51. Farini R, Fabris C, Bonvicini P, et al. CA 19-9 in the differential diagnosis between pancreatic cancer and chronic pancreatitis. Eur J Cancer Clin Oncol 1985; 21(4): 429-32.
52. Firpo MA, Gay DZ, Granger SR, et al. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg 2009; 33(4): 716-22.
53. Gansauge F, Gansauge S, Parker N, et al. CAM 17.1--a new diagnostic marker in pancreatic cancer. Br J Cancer 1996; 74(12): 1997-2002.
54. Goonetilleke KS, Mason JM, Siriwardana P, King NK, France MW, Siriwardena AK. Diagnostic and prognostic value of plasma tumor M2 pyruvate kinase in periampullary cancer: evidence for a novel biological marker of adverse prognosis. Pancreas 2007; 34(3): 318-24.
55. Gupta MK, Arciaga R, Bocci L, Tubbs R, Bukowski R, Deodhar SD. Measurement of a monoclonal-antibodydefined antigen (CA19-9) in the sera of patients with malignant and nonmalignant diseases. Comparison with carcinoembryonic antigen. Cancer 1985; 56(2): 277-83.
56. Hayakawa T, Kondo T, Shibata T, et al. Sensitive serum markers for detecting pancreatic cancer. Cancer 1988; 61(9): 1827-31.
57. Hayakawa T, Naruse S, Kitagawa M, et al. A prospective multicenter trial evaluating diagnostic validity of multivariate analysis and individual serum marker in differential diagnosis of pancreatic cancer from benign pancreatic diseases. Int J Pancreatol 1999; 25(1): 23-9.
58. Hedstrom J, Haglund C, Kemppainen E, Leinimaa M, Leinonen J, Stenman UH. Time-resolved immunofluorometric assay of trypsin-1 complexed with alpha(1)-antitrypsin in serum: increased immunoreactivity in patients with biliary tract cancer. Clin Chem 1999; 45(10): 1768-73.
59. Heptner G, Domschke S, Domschke W. Comparison of CA 72-4 with CA 19-9 and carcinoembryonic antigen in the serodiagnostics of gastrointestinal malignancies. Scand J Gastroenterol 1989; 24(6): 745-50.
60. Hyoty M, Hyoty H, Aaran RK, Airo I, Nordback I. Tumour antigens CA 195 and CA 19-9 in pancreatic juice and serum for the diagnosis of pancreatic carcinoma. Eur J Surg 1992; 158(3): 173-9.
61. Iishi H, Yamamura H, Tatsuta M, Okuda S, Kitamura T. Value of ultrasonographic examination combined with measurement of serum tumor markers in the diagnosis of pancreatic cancer of less than 3 cm in diameter. Cancer 1986; 57(10): 1947-51.
62. Jalanko H, Kuusela P, Roberts P, Sipponen P, Haglund CA, Makela O. Comparison of a new tumour marker, CA 19-9, with alpha-fetoprotein and carcinoembryonic antigen in patients with upper gastrointestinal diseases. J Clin Pathol 1984; 37(2): 218-22.
63. Jansa R, Prezelj J, Kocijancic A, Osredkar J, Ferlic F. Androstanediol glucuronide in patients with pancreatic cancer and in those with chronic pancreatitis. Horm Metab Res 1996; 28(8): 381-3.
64. Jiang XT, Tao HQ, Zou SC. Detection of serum tumor markers in the diagnosis and treatment of patients with pancreatic cancer. Hepatobiliary Pancreat Dis Int 2004; 3(3): 464-8.
65. Joergensen MT, Heegaard NH, Schaffalitzky de Muckadell OB. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer. Pancreas 2010; 39(2): 243-7.
66. Kim HJ, Kim MH, Myung SJ, et al. A new strategy for the application of CA19-9 in the differentiation of pancreaticobiliary cancer: analysis using a receiver operating characteristic curve. Am J Gastroenterol 1999; 94(7): 1941-6.
67. Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res 2006; 12(2): 442-6.
68. Kuusela P, Haglund C, Roberts PJ. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases. Br J Cancer 1991; 63(4): 636-40.
69. Liao Q, Zhao YP, Yang YC, Li LJ, Long X, Han SM. Combined detection of serum tumor markers for differential diagnosis of solid lesions located at the pancreatic head. Hepatobiliary Pancreat Dis Int 2007; 6(6): 641-5.
70. Liao WC, Wu MS, Wang HP, Tien YW, Lin JT. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. Pancreas 2009; 38(4): 422-6.
71. Louhimo J, Alfthan H, Stenman UH, Haglund C. Serum HCG beta and CA 72-4 are stronger prognostic factors than CEA, CA 19-9 and CA 242 in pancreatic cancer. Oncology 2004; 66(2): 126-31.
72. Malesci A, Tommasini MA, Bonato C, et al. Determination of CA 19-9 antigen in serum and pancreatic juice for differential diagnosis of pancreatic adenocarcinoma from chronic pancreatitis. Gastroenterology 1987; 92(1): 60-7.
73. Matsumoto S, Harada H, Tanaka J, et al. Evaluation of cytology and tumor markers of pure pancreatic juice for the diagnosis of pancreatic cancer at early stages. Pancreas 1994; 9(6): 741-7.
74. Meggiato T, Basso D, Fabris C, et al. CAR-3 and CA 19-9 serum levels in pancreatic cancer: any differences between two epitopes of the same mucin-like glycoprotein? Dis Markers 1990; 8(4): 171-7.
75. Ni XG, Bai XF, Mao YL, et al. The clinical value of serum CEA, CA19-9, and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 2005; 31(2): 164-9.
76. Nishida K, Tasaki N, Miyagawa H, Yoshikawa T, Kondo M. Estimation of carbohydrate antigen (CA) 19-9 levels in pure pancreatic juice of patients with pancreatic cancer. Am J Gastroenterol 1988; 83(2): 126-9.
77. Ozkan H, Kaya M, Cengiz A. Comparison of tumor marker CA 242 with CA 19-9 and carcinoembryonic antigen (CEA) in pancreatic cancer. Hepatogastroenterology. 2003; 50(53): 1669-74.
78. Pasquali C, Sperti C, D'Andrea AA, et al. Evaluation of carbohydrate antigens 19-9 and 12-5 in patients with pancreatic cancer. Pancreas 1987; 2(1): 34-7.
79. Piantino P, Andriulli A, Gindro T, et al. CA 19-9 assay in differential diagnosis of pancreatic carcinoma from inflammatory pancreatic diseases. Am J Gastroenterol 1986; 81(6): 436-9.
80. Plebani M, Basso D, Del Favero G, et al. Clinical utility of TPS, TPA and CA 19-9 measurement in pancreatic cancer. Oncology 1993; 50(6): 436-40.
81. Raedle J, Oremek G, Welker M, Roth WK, Caspary WF, Zeuzem S. p53 autoantibodies in patients with pancreatitis and pancreatic carcinoma. Pancreas 1996; 13(3): 241-6.
82. Robles-Diaz G, Diaz-Sanchez V, Fernandez-del Castillo C, et al. Serum testosterone:dihydrotestosterone ratio and CA 19-9 in the diagnosis of pancreatic cancer. Am J Gastroenterol 1991; 86(5): 591-4.
83. Safi F, Schlosser W, Falkenreck S, Beger HG. Prognostic value of CA 19-9 serum course in pancreatic cancer. Hepatogastroenterology 1998; 45(19): 253-9.
84. Sakahara H, Endo K, Nakajima K, et al. Serum CA 19-9 concentrations and computed tomography findings in patients with pancreatic carcinoma. Cancer 1986; 57(7): 1324-6.
85. Sakamoto K, Haga Y, Yoshimura R, Egami H, Yokoyama Y, Akagi M. Comparative effectiveness of the tumour diagnostics, CA 19-9, CA 125 and carcinoembryonic antigen in patients with diseases of the digestive system. Gut 1987; 28(3): 323-9.
86. Satake K, Kanazawa G, Kho I, Chung Y, Umeyama K. Evaluation of serum pancreatic enzymes, carbohydrate antigen 19-9, and carcinoembryonic antigen in various pancreatic diseases. Am J Gastroenterol 1985; 80(8): 630-6.
87. Savarino V, Mansi C, Pugliese V, Ferrara GB, Arcuri V, Celle G. Evaluation of a new tumor-associated antigen in pancreatic cancer. Digestion 1984; 29(1): 1-4.
88. Slesak B, Harlozinska-Szmyrka A, Knast W, Sedlaczek P, van Dalen A, Einarsson R. Tissue polypeptide specific antigen (TPS), a marker for differentiation between pancreatic carcinoma and chronic pancreatitis. A comparative study with CA 19-9. Cancer 2000; 89(1): 83-8.
89. Steinberg WM, Gelfand R, Anderson KK, et al. Comparison of the sensitivity and specificity of the CA19-9 and carcinoembryonic antigen assays in detecting cancer of the pancreas. Gastroenterology 1986; 90(2): 343-9.
90. Tatsuta M, Yamamura H, Iishi H, et al. Values of CA 19-9 in the serum, pure pancreatic juice, and aspirated pancreatic material in the diagnosis of malignant pancreatic tumor. Cancer 1985; 56(11): 2669-73.
91. Wang TH, Lin JT, Chen DS, Sheu JC, Sung JL. Noninvasive diagnosis of advanced pancreatic cancer by real-time ultrasonography, carcinoembryonic antigen, and carbohydrate antigen 19-9. Pancreas 1986; 1(3): 219-23.
92. Wu D, Qian JM, Deng RX, et al. Evaluating the role of serum elastase 1 in the diagnosis of pancreatic cancer. Chin J Dig Dis 2006; 7(2): 117-20.
93. Yoshikawa T, Nishida K, Tanigawa M, Fukumoto K, Kondo M. Carbohydrate antigenic determinant (CA 19-9) and other tumor markers in gastrointestinal malignancies. Digestion 1985; 31(2-3): 67-76.
94. Mroczko B, Lukaszewicz-Zajac M, Wereszczynska-Siemiatkowska U, et al. Clinical significance of the measurements of serum matrix metalloproteinase-9 and its inhibitor (tissue inhibitor of metalloproteinase-1) in patients with pancreatic cancer: metalloproteinase-9 as an independent prognostic factor. Pancreas 2009; 38(6): 613-8.
95. Pleskow DK, Berger HJ, Gyves J, Allen E, McLean A, Podolsky DK. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med 1989; 110(9): 704-9.